Table 2. Clinicopathological features of the breast cancer cohort and association with BAG-1 expression.

	Nuclear BAG-1			Cytoplasmic BAG-1
	Positive	Negative	P-value	Positive	Negative	P-value
(A) Clinicopathological characteristics and associations with BAG-1 expression
Age
>50	135	39	0.979	135	39	0.252
<50	79	23		85	17
Grade
1 and 2	133	17	<0.0001	129	21	0.005
3	81	45		91	35
Size
>20 mm	81	31	0.086	82	30	0.027
<20 mm	133	31		138	26
Nodal status
Positive	90	30	0.424	98	22	0.429
Negative	121	32		119	34
HER-2
Positive	31	20	0.001	32	19	0.001
Negative	180	40		184	36
ER
Positive	169	20	<0.0001	166	23	<0.0001
Negative	44	41		52	33
PR
Positive	146	13	<0.0001	141	18	<0.0001
Negative	67	49		78	38
CK5/6
Positive	19	14	0.003	23	10	0.127
Negative	195	48		197	46
Triple negative
Positive	25	23	<0.0001	31	17	0.0039
Negative	187	37		186	38
(B) Treatment and survival data		n(%)
Endocrine therapy		144/292 (49.3)
Chemotherapy		111/292 (38.0)
Endocrine and chemotherapy		71/292 (24.3)
Recurrences		75/292 (25.7)
Distant metastases		68/292 (23.3)
Deaths		67/292 (22.9)
Breast cancer-specific deaths		52/292 (17.8)
5-year disease-free survival		74.0%
5-year metastasis-free survival		76.8%
5-year breast cancer-specific survival		86.0%